This phase II trial failed to identify any activity of bisantrene in patients with recurrent or metastatic colorectal cancer who had not received previous chemotherapy for metastatic disease. Side effects were fever, chills, and phlebitis. At this dose and schedule bisantrene is inactive in this disease.
|Original language||English (US)|
|Number of pages||2|
|Journal||Cancer treatment reports|
|State||Published - 1982|
ASJC Scopus subject areas
- Cancer Research